173 related articles for article (PubMed ID: 36830313)
1. ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance.
Chen M; Yang Y; Ying Y; Huang J; Sun M; Hong M; Wang H; Xie S; Chen D
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830313
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
3. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.
Lagas JS; Sparidans RW; van Waterschoot RA; Wagenaar E; Beijnen JH; Schinkel AH
Antimicrob Agents Chemother; 2008 Mar; 52(3):1034-9. PubMed ID: 18195061
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp.
Zhao T; Li X; Chen Y; Du J; Chen X; Wang D; Wang L; Zhao S; Wang C; Meng Q; Sun H; Liu K; Wu J
Front Pharmacol; 2022; 13():914842. PubMed ID: 36071847
[TBL] [Abstract][Full Text] [Related]
7. A proposed "steric-like effect" for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism.
Xu X; Lu Q; Yang Y; Martínez MA; Lopez-Torres B; Martínez-Larrañaga MR; Wang X; Anadón A; Ares I
Chemosphere; 2021 Dec; 284():131347. PubMed ID: 34323809
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
9. Relationship between permeability glycoprotein (P-gp) gene expression and enrofloxacin metabolism in Nile Tilapia.
Hu K; Cheng G; Zhang H; Wang H; Ruan J; Chen L; Fang W; Yang X
J Aquat Anim Health; 2014 Jun; 26(2):59-65. PubMed ID: 24895858
[TBL] [Abstract][Full Text] [Related]
10. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Zhang Y; Huang J; Liu Y; Guo T; Wang L
Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
[TBL] [Abstract][Full Text] [Related]
11. Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin.
Guo M; Dai X; Hu D; Zhang Y; Sun Y; Ren W; Wang L
Poult Sci; 2016 Sep; 95(9):2129-35. PubMed ID: 27118859
[TBL] [Abstract][Full Text] [Related]
12. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
13. Minimal Involvement of P-gp and BCRP in Oral Absorption of Ensitrelvir, An Oral SARS-CoV-2 3C-like Protease Inhibitor, in a Non-Clinical Investigation.
Watari R; Tamura N; Yoshida S; Kido Y; Matsuzaki T
J Pharm Sci; 2024 Jun; ():. PubMed ID: 38885812
[TBL] [Abstract][Full Text] [Related]
14. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
15. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
16. Effect of enrofloxacin and roxarsone on CYP450s in pig.
Li Y; Jiang M; Thunders M; Ai X; Qiu J
Res Vet Sci; 2018 Apr; 117():97-98. PubMed ID: 29202315
[TBL] [Abstract][Full Text] [Related]
17. Quantification of residual enrofloxacin and ciprofloxacin in feathers of broiler chickens by high-performance liquid chromatography-fluorescence after oral administration of the drugs.
Haag G; Marin GH; Errecalde J
J Adv Pharm Technol Res; 2016; 7(1):2-5. PubMed ID: 26955603
[TBL] [Abstract][Full Text] [Related]
18. The effects of cyclosporine A or activated charcoal co-administration on the pharmacokinetics of enrofloxacin in chickens.
Petkova T; Milanova A; Poźniak B
Poult Sci; 2023 Jan; 102(1):102225. PubMed ID: 36343435
[TBL] [Abstract][Full Text] [Related]
19. Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study.
Poapolathep S; Chomcheun T; Giorgi M; Jualaong S; Klangkaew N; Phaochoosak N; Udomkusonsri P; Marin P; Poapolathep A
J Vet Pharmacol Ther; 2021 Jul; 44(4):575-582. PubMed ID: 33107624
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure.
Marchitti SA; Mazur CS; Dillingham CM; Rawat S; Sharma A; Zastre J; Kenneke JF
Toxicol Sci; 2017 Jan; 155(1):270-282. PubMed ID: 28031414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
